The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Imatinib: A Breakthrough of Targeted Therapy in Cancer
Open accessAbstract
Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach to management of various cancers and represents a therapeutic breakthrough. Imatinib was one of the first cancer therapies to show the potential for such targeted action. Imatinib, an oral targeted therapy, inhibits tyrosine kinases specifically BCR-ABL, c-KIT, and PDGFRA. Apart from its remarkable success in CML and GIST, Imatinib benefits various other tumors caused by Imatinib-specific abnormalities of PDGFR and c-KIT. Imatinib has also been proven to be effective in steroid-refractory chronic graft-versus-host disease because of its anti-PDGFR action. This paper is a comprehensive review of the role of Imatinib in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Somatic Activation of KIT in Distinct Subtypes of Melanoma
Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60500-6 · Cited by 1,369
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4452 · Cited by 1,073
Methods in molecular medicine.
Craig, R. K. (1987) · BMJ · doi:10.1136/bmj.295.6599.646 · Cited by 1,057
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Blanke, C. D., Demetri, G. D., von Mehren, M., Heinrich, M. C., Eisenberg, B., Fletcher, J. A., Corless, C. L., Fletcher, C. D. M., Roberts, P. J., Heinz, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4403 · Cited by 996
Joensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J. T., Pink, D., Schütte, J., Ramadori, G., Hohenberger, P., Duyster, J., Al-Batran, S.-E., et al. (2012) · JAMA · doi:10.1001/jama.2012.347 · Cited by 980
Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., Blay, J.-Y., Leyvraz, S., Stul, M., Casali, P. G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.030 · Cited by 892
KIT as a Therapeutic Target in Metastatic Melanoma
Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 888
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Clinical Pharmacokinetics of Imatinib
Peng, B., Lloyd, P., & Schran, H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544090-00001 · Cited by 665
Hodi, F. S., Corless, C. L., Giobbie-Hurder, A., Fletcher, J. A., Zhu, M., Marino-Enriquez, A., Friedlander, P., Gonzalez, R., Weber, J. S., Gajewski, T. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7836 · Cited by 608
KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications
Medeiros, F., Corless, C. L., Duensing, A., Hornick, J. L., Oliveira, A. M., Heinrich, M. C., Fletcher, J. A., & Fletcher, C. D. M. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00007 · Cited by 486
McArthur, G. A., Demetri, G. D., van Oosterom, A., Heinrich, M. C., Debiec-Rychter, M., Corless, C. L., Nikolova, Z., Dimitrijevic, S., & Fletcher, J. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.088 · Cited by 482
Verweij, J., van Oosterom, A., Blay, J.-Y., Judson, I., Rodenhuis, S., van der Graaf, W., Radford, J., Le Cesne, A., Hogendoorn, P. C. W., di Paola, E. D., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00836-5 · Cited by 404
Blay, J.-Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0183 · Cited by 392
Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 386
Fielding, A. K., Rowe, J. M., Buck, G., Foroni, L., Gerrard, G., Litzow, M. R., Lazarus, H., Luger, S. M., Marks, D. I., McMillan, A. K., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529008 · Cited by 378
Zalcberg, J. R., Verweij, J., Casali, P. G., Le Cesne, A., Reichardt, P., Blay, J.-Y., Schlemmer, M., Van Glabbeke, M., Brown, M., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.034 · Cited by 378
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Vigneri, P., & Wang, J. Y. J. (2001) · Nature Medicine · doi:10.1038/84683 · Cited by 331
Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F., Kiani, A., Schwerdtfeger, R., Vogelsang, G. B., et al. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.05.011 · Cited by 327
Eosinophilia: secondary, clonal and idiopathic
Tefferi, A., Patnaik, M. M., & Pardanani, A. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06038.x · Cited by 298
Seggewiss, R. (2005) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290
Optimizing Treatment of Desmoid Tumors
Lev, D., Kotilingam, D., Wei, C., Ballo, M. T., Zagars, G. K., Pisters, P. W. T., Lazar, A. A., Patel, S. R., Benjamin, R. S., & Pollock, R. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5015 · Cited by 280
Van Glabbeke, M., Verweij, J., Casali, P. G., Le Cesne, A., Hohenberger, P., Ray-Coquard, I., Schlemmer, M., van Oosterom, A. T., Goldstein, D., Sciot, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.601 · Cited by 280
Phase II Study of Imatinib in Advanced Chordoma
Stacchiotti, S., Longhi, A., Ferraresi, V., Grignani, G., Comandone, A., Stupp, R., Bertuzzi, A., Tamborini, E., Pilotti, S., Messina, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3656 · Cited by 276
Imatinib for systemic mast-cell disease
Pardanani, A., Elliott, M., Reeder, T., Li, C.-Y., Baxter, E., Cross, N., & Tefferi, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14115-3 · Cited by 247
Antonescu, C. R., Busam, K. J., Francone, T. D., Wong, G. C., Guo, T., Agaram, N. P., Besmer, P., Jungbluth, A., Gimbel, M., Chen, C., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22681 · Cited by 245
Penel, N., Le Cesne, A., Bui, B. N., Perol, D., Brain, E. G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq341 · Cited by 235
Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4575 · Cited by 213
Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., Larson, R. A., O’Brien, S. G., Dobrez, D. G., Hensley, M. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.154 · Cited by 204
Imatinib treatment: Specific issues related to safety, fertility, and pregnancy
Hensley, M. L., & Ford, J. M. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70016-x · Cited by 199
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate
Mace, J., Sybil Biermann, J., Sondak, V., McGinn, C., Hayes, C., Thomas, D., & Baker, L. (2002) · Cancer · doi:10.1002/cncr.11029 · Cited by 193
Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion
Peng, B., Dutreix, C., Mehring, G., Hayes, M. J., Ben‐Am, M., Seiberling, M., Pokorny, R., Capdeville, R., & Lloyd, P. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262101 · Cited by 165
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H. M., & Verstovsek, S. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.12.020 · Cited by 163
Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
Eechoute, K., Sparreboom, A., Burger, H., Franke, R. M., Schiavon, G., Verweij, J., Loos, W. J., Wiemer, E. A. C., & Mathijssen, R. H. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2250 · Cited by 160
Tefferi, A., Gotlib, J. R., & Pardanani, A. D. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0503 · Cited by 155
Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Shan, J., O'Brien, S. M., Reddy, N., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Verstovšek, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154344 · Cited by 155
Kérob, D., Porcher, R., VEROLA, O., Dalle, S., Maubec, E., Aubin, F., D'Incan, M., Bodokh, I., Boulinguez, S., Madelaine, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3401 · Cited by 145
Reichardt, P., Blay, J., Gelderblom, H. A. J., Schlemmer, M., Demetri, G. D., Bui-Nguyen, B., McArthur, G. A., Yazji, S., Hsu, Y., Galetić, I., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr598 · Cited by 142
Pardanani, A. D., Ketterling, R. P., Li, C. Y., Patnaik, M. M., Wolanskyj, A. P., Elliott, M. A., Camoriano, J. K., Butterfield, J. H., Dewald, G., & Tefferi, A. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.11.011 · Cited by 141
Desai, J., Shankar, S., Heinrich, M. C., Fletcher, J. A., Fletcher, C. D. �., Manola, J., Morgan, J. A., Corless, C. L., George, S., Tuncali, K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0858 · Cited by 135
Demetri, G. D., Heinrich, M. C., Fletcher, J. A., Fletcher, C. D. �., den Abbeele, A. D. V., Corless, C. L., Antonescu, C. R., George, S., Morgan, J. A., Chen, M. H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0482 · Cited by 133
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Pardanani, A. D., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-01-0246 · Cited by 131
A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer
Ha, H. T., Lee, J. J., Urba, S. G., Koenig, R. J., Sisson, J. C., Giordano, T. J., & Worden, F. P. (2010) · Thyroid · doi:10.1089/thy.2010.0057 · Cited by 129
Ovarian cancer: a focus on management of recurrent disease
Herzog, T. J., & Pothuri, B. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0637 · Cited by 112
Koon, H. B., Krown, S. E., Lee, J. Y., Honda, K. S., Rapisuwon, S., Wang, Z., Aboulafia, D. M., Reid, E. G., Rudek, M. A., Dezube, B. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.6365 · Cited by 111
Apte, S. M., Fan, D., Killion, J. J., & Fidler, I. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1151-3 · Cited by 105
Olivieri, A., Cimminiello, M., Corradini, P., Mordini, N., Fedele, R., Selleri, C., Onida, F., Patriarca, F. F., Pavone, E., Svegliati, S., et al. (2013) · Blood · doi:10.1182/blood-2013-05-494278 · Cited by 101
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate
Labropoulos, S. V., Fletcher, J. A., Oliveira, A. M., Papadopoulos, S., & Razis, E. D. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200504000-00014 · Cited by 100
Price, V. E., Fletcher, J. A., Zieleńska, M., Cole, W. G., Viero, S., Manson, D. E., Stuart, M., & Pappo, A. S. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20249 · Cited by 86
Pathogenesis, clinical features, and treatment advances in mastocytosis
Pardanani, A. D., Akin, C., & Valent, P. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.07.010 · Cited by 83
The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells
Podtcheko, A., Ohtsuru, A., Tsuda, S., Namba, H., Saenko, V., Nakashima, M., Mitsutake, N., Kanda, S., Kurebayashi, J., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021230 · Cited by 82
Alberts, D. S., Liu, P. Y., Wilczynski, S. P., JANG, A., MOON, J., Ward, J. H., BECK, J. T., Clouser, M. C., & Markman, M. M. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00882.x · Cited by 70
Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
Branford, S., & Hughes, T. P. (2006) · Humana Press eBooks · doi:10.1385/1-59745-017-0:93 · Cited by 68
Neoadjuvant Imatinib Therapy for Dermatofibrosarcoma Protuberans
Han, A., Chen, E. H., Niedt, G. W., Sherman, W. H., & Ratner, D. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.140 · Cited by 66
A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer
Posadas, E. M., Kwitkowski, V. E., Kotz, H. L., Espina, V. A., Minasian, L. M., Tchabo, N. E., Premkumar, A., Hussain, M. M., Chang, R., Steinberg, S. M., et al. (2007) · Cancer · doi:10.1002/cncr.22757 · Cited by 60
C-kit Asp-816-Val Mutation Analysis in Patients with Mastocytosis
Verzijl, A., Heide, R., Oranje, A. P., & van Schaik, R. H. N. (2006) · Dermatology · doi:10.1159/000096907 · Cited by 56
Advanced mast cell disease: an Italian Hematological Multicenter experience
Pagano, L., Valentini, C. G., Caira, M., Rondoni, M., Lint, M. T. V., Candoni, A., Allione, B., Cattaneo, C. M., Marbello, L., Caramatti, C., et al. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0166-4 · Cited by 48
Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia: A New Era of Challenges
Thomas, D. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.435 · Cited by 46
Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations
Kang, H. J., Koh, K. H., Yang, E., You, K. T., Kim, H. J., Paik, Y., & Kim, H. (2006) · PROTEOMICS · doi:10.1002/pmic.200500372 · Cited by 45
Targeted therapy in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., Ghanem, H., O'Brien, S. M., & Kantarjian, H. M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.99 · Cited by 43
Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside
Olivieri, J., Coluzzi, S., Attolico, I., & Olivieri, A. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/924954 · Cited by 32
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes
Kumari, S., Carmona, A. V., Tiwari, A. K., & Trippier, P. C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00530 · Cited by 654
Khwaja, A., Bjorkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E., Burnett, A., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 592
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 359
Metal–organic frameworks for chemical sensing devices
Olorunyomi, J. F., Geh, S. T., Caruso, R. A., & Doherty, C. M. (2021) · Materials Horizons · doi:10.1039/d1mh00609f · Cited by 327
Metadata
- Authors
- Iqbal, N., & Iqbal, N.
- Venue
- Chemotherapy Research and Practice
- Publisher
- Wiley
- Published
- 2014-05-19
- Volume
- 2014
- Pages
- 1-9
- ISSN
- 2090-2107 (ISSN-L)
- 2090-2115
- OpenAlex
- W2043759232
- Cited by
- 470
- References
- 79
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.